Business Context and Reporting Period
This Form 8-K was filed by Akebia Therapeutics, Inc. on July 28, 2016, reporting events occurring on that date and effective July 29, 2016. The filing primarily addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate events and does not contain financial statements or performance metrics.
Material Changes
- Board Election: The Board of Directors elected Scott A. Canute as a Class II Director to fill a vacancy.
- Effective Date: The appointment is effective as of July 29, 2016.
- Term Duration: Mr. Canute's initial term will last until the 2019 annual meeting of stockholders.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding business operations. It notes that Mr. Canute will receive compensation in accordance with the Company's non-employee director compensation policy described in the definitive proxy statement filed on April 29, 2016, and will enter into a customary indemnification agreement. A press release dated August 2, 2016, announcing the election is included as an exhibit.
Investor Verification Checklist
- Verify the specific terms of the non-employee director compensation policy referenced in the April 29, 2016 proxy statement.
- Confirm the background and qualifications of Scott A. Canute as disclosed in the attached press release (Exhibit 99.1).
- Review the Company's most recent 10-Q or 10-K for current financial status, as this 8-K contains no financial data.